Cizzle Biotechnology Holdings PLC (GB:CIZ) has released an update.
Cizzle Biotechnology Holdings PLC, a UK-based diagnostics developer, is nearing the completion of a strategic licensing agreement in North America with Cizzle Bio Inc., focusing on the marketization of their CIZ1B biomarker for early lung cancer detection. The deal will build upon Cizzle’s recent collaborative efforts, including a significant partnership with Moffitt Cancer Center for testing patients with lung nodules. The company’s innovative blood test aims to offer a non-intrusive and cost-effective solution for early-stage cancer detection, leveraging collaborations with prominent cancer centers.
For further insights into GB:CIZ stock, check out TipRanks’ Stock Analysis page.
